3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 1/2
1
Status
Recruiting
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Genitourinary
2
Conditions
Prostatic Neoplasms, Castration-Resistant
1
Prostatic Neoplasms
1
Interventions
Specimen Handling
122
pembrolizumab
118
Magnetic Resonance Spectroscopy
107
Carboplatin
86
Cyclophosphamide
75
Biopsy
68
Cisplatin
63
Paclitaxel
58
Bevacizumab
56
Gemcitabine
49
Nivolumab
47
fludarabine
44
Dexamethasone
39
Rituximab
38
Pemetrexed
38
Fluorouracil
37
atezolizumab
36
Docetaxel
36
Doxorubicin
34
Radiotherapy
33
Leucovorin
33
venetoclax
31
Oxaliplatin
30
Capecitabine
30
Temozolomide
28
Prednisone
28
Standard of Care
27
Radiation
27
Letrozole
27
Cetuximab
27
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Recruiting
×
fludrocortisone acetate
×
30 days
×
Clear all
NCT06136650
2026-06-03
MK-5684-004
Merck Sharp & Dohme LLC
Phase 3
Recruiting
1,314 enrolled
NCT06353386
2026-05-26
MK-5684-01A
Merck Sharp & Dohme LLC
Phase 1/2
Recruiting
220 enrolled